Top Markets
Coin of the day
Evaxion Biotech A/S Evaxion Biotech A/S

Evaxion Biotech A/S

EVAX
Classement en actions #29692
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to... Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Prix de l'action
$3.05
Capitalisation boursière
$19.27M
Changement (1 jour)
-3.17%
Changement (1 an)
0.33%
Pays
DK
Échange Evaxion Biotech A/S (EVAX)

Catégorie

Ratio P/S pour Evaxion Biotech A/S (EVAX)
Ratio P/S au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Evaxion Biotech A/S, le ratio cours/ventes actuel (TTM) est 0. À la fin de 2026, le ratio P/S était de 0.
Historique du ratio P/S pour Evaxion Biotech A/S de 2026 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
Pas assez de données pour les dates fournies.
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
10.17 -
US
10.13 -
NL
11.28 -
US
2.95 -
AU
- -
CH